278 related articles for article (PubMed ID: 19622019)
1. Concomitant delivery of a CTL-restricted peptide antigen and CpG ODN by PLGA microparticles induces cellular immune response.
Fischer S; Schlosser E; Mueller M; Csaba N; Merkle HP; Groettrup M; Gander B
J Drug Target; 2009 Sep; 17(8):652-61. PubMed ID: 19622019
[TBL] [Abstract][Full Text] [Related]
2. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology.
San Román B; Irache JM; Gómez S; Tsapis N; Gamazo C; Espuelas MS
Eur J Pharm Biopharm; 2008 Sep; 70(1):98-108. PubMed ID: 18501572
[TBL] [Abstract][Full Text] [Related]
3. Surface modification of poly(D,L-lactic-co-glycolic acid) nanoparticles with protamine enhanced cross-presentation of encapsulated ovalbumin by bone marrow-derived dendritic cells.
Han R; Zhu J; Yang X; Xu H
J Biomed Mater Res A; 2011 Jan; 96(1):142-9. PubMed ID: 21105162
[TBL] [Abstract][Full Text] [Related]
4. The preservation of phenotype and functionality of dendritic cells upon phagocytosis of polyelectrolyte-coated PLGA microparticles.
Fischer S; Uetz-von Allmen E; Waeckerle-Men Y; Groettrup M; Merkle HP; Gander B
Biomaterials; 2007 Feb; 28(6):994-1004. PubMed ID: 17118442
[TBL] [Abstract][Full Text] [Related]
5. Time course study of the antigen-specific immune response to a PLGA microparticle vaccine formulation.
Wang Q; Tan MT; Keegan BP; Barry MA; Heffernan MJ
Biomaterials; 2014 Sep; 35(29):8385-93. PubMed ID: 24986256
[TBL] [Abstract][Full Text] [Related]
6. Surface coating of PLGA microparticles with protamine enhances their immunological performance through facilitated phagocytosis.
Martínez Gómez JM; Csaba N; Fischer S; Sichelstiel A; Kündig TM; Gander B; Johansen P
J Control Release; 2008 Sep; 130(2):161-7. PubMed ID: 18588928
[TBL] [Abstract][Full Text] [Related]
7. Co-encapsulated CpG oligodeoxynucleotides and ovalbumin in PLGA microparticles; an in vitro and in vivo study.
San Román B; Gómez S; Irache JM; Espuelas S
J Pharm Pharm Sci; 2014; 17(4):541-53. PubMed ID: 25579433
[TBL] [Abstract][Full Text] [Related]
8. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
Wakita D; Chamoto K; Zhang Y; Narita Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100
[TBL] [Abstract][Full Text] [Related]
9. One-step preparation of polyelectrolyte-coated PLGA microparticles and their functionalization with model ligands.
Fischer S; Foerg C; Ellenberger S; Merkle HP; Gander B
J Control Release; 2006 Mar; 111(1-2):135-44. PubMed ID: 16377017
[TBL] [Abstract][Full Text] [Related]
10. Coencapsulation of tumor lysate and CpG-ODN in PLGA-microspheres enables successful immunotherapy of prostate carcinoma in TRAMP mice.
Mueller M; Reichardt W; Koerner J; Groettrup M
J Control Release; 2012 Aug; 162(1):159-66. PubMed ID: 22709589
[TBL] [Abstract][Full Text] [Related]
11. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses.
Schlosser E; Mueller M; Fischer S; Basta S; Busch DH; Gander B; Groettrup M
Vaccine; 2008 Mar; 26(13):1626-37. PubMed ID: 18295941
[TBL] [Abstract][Full Text] [Related]
12. Poly(D,L-lactic-co-glycolic acid) microsphere delivery of adenovirus for vaccination.
Wang D; Molavi O; Lutsiak ME; Elamanchili P; Kwon GS; Samuel J
J Pharm Pharm Sci; 2007; 10(2):217-30. PubMed ID: 17706180
[TBL] [Abstract][Full Text] [Related]
13. Orally administered OVA/CpG-ODN induces specific mucosal and systemic immune response in young and aged mice.
Alignani D; Maletto B; Liscovsky M; Rópolo A; Morón G; Pistoresi-Palencia MC
J Leukoc Biol; 2005 Jun; 77(6):898-905. PubMed ID: 15758079
[TBL] [Abstract][Full Text] [Related]
14. Diaminosulfide based polymer microparticles as cancer vaccine delivery systems.
Geary SM; Hu Q; Joshi VB; Bowden NB; Salem AK
J Control Release; 2015 Dec; 220(Pt B):682-90. PubMed ID: 26359124
[TBL] [Abstract][Full Text] [Related]
15. Co-delivery of ovalbumin and CpG motifs into microparticles protected sensitized mice from anaphylaxis.
San Román B; Irache JM; Gómez S; Gamazo C; Espuelas S
Int Arch Allergy Immunol; 2009; 149(2):111-8. PubMed ID: 19127067
[TBL] [Abstract][Full Text] [Related]
16. Immunological responses after immunisation of mice with microparticles containing antigen and single stranded RNA (polyuridylic acid).
Westwood A; Elvin SJ; Healey GD; Williamson ED; Eyles JE
Vaccine; 2006 Mar; 24(11):1736-43. PubMed ID: 16278038
[TBL] [Abstract][Full Text] [Related]
17. Encapsulation of antigen in poly(D,L-lactide-co-glycolide) microspheres protects from harmful effects of γ-irradiation as assessed in mice.
Mohanan D; Gander B; Kündig TM; Johansen P
Eur J Pharm Biopharm; 2012 Feb; 80(2):274-81. PubMed ID: 22024408
[TBL] [Abstract][Full Text] [Related]
18. Co-encapsulation of antigen and Toll-like receptor ligand in cationic liposomes affects the quality of the immune response in mice after intradermal vaccination.
Bal SM; Hortensius S; Ding Z; Jiskoot W; Bouwstra JA
Vaccine; 2011 Jan; 29(5):1045-52. PubMed ID: 21129393
[TBL] [Abstract][Full Text] [Related]
19. Induction of cytotoxic T-lymphocytes by electroporation-enhanced needle-free skin immunization.
Zhao YL; Murthy SN; Manjili MH; Guan LJ; Sen A; Hui SW
Vaccine; 2006 Feb; 24(9):1282-90. PubMed ID: 16225969
[TBL] [Abstract][Full Text] [Related]
20. A comparative study of the antigen-specific immune response induced by co-delivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles.
Zhang XQ; Dahle CE; Weiner GJ; Salem AK
J Pharm Sci; 2007 Dec; 96(12):3283-92. PubMed ID: 17497736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
